AA
BDTX icon

AlphaCentric Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

AlphaCentric Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,625
Closed -$130K – 261
2025
Q4 		$130K Buy
+53,625
New +$190K 0.13% 193

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AlphaCentric Advisors's BDTX Position: Q1 2026 in Review

AlphaCentric Advisors sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 53,625 shares — an estimated $130K sold.

AlphaCentric Advisors first reported a position in BDTX in Q4 2025 and held it in 1 quarter. The position peaked at $130K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • AlphaCentric Advisors reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaCentric Advisors sold 53,625 Black Diamond Therapeutics shares in Q1 2026, an estimated $130K.
  • AlphaCentric Advisors first reported a position in Black Diamond Therapeutics in Q4 2025 and held it in 1 quarter.
  • AlphaCentric Advisors's Black Diamond Therapeutics position peaked at $130K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.